Drug Profile
Research programme: anti-inducible T-cell co-stimulator monoclonal antibodies - AstraZeneca/Japan Tobacco
Alternative Names: Anti-ICOS; Anti-ICOS monoclonal antibodyLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Developer AstraZeneca; Japan Tobacco
- Class Monoclonal antibodies
- Mechanism of Action Inducible T-cell co-stimulator protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 May 2019 No recent reports of development identified for preclinical development in Inflammation in Japan (Parenteral)
- 28 May 2019 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)